SPPAM
LENZ

Summit Partners Public Asset Management’s LENZ Therapeutics LENZ Stock Holding History

Summit Partners Public Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-323,857
Closed -$15.1M – 219
2025
Q3 		$15.1M Buy
323,857
+83,857
+35% +$3.08M 0.31% 85
2025
Q2 		$7.03M Buy
+240,000
New +$6.53M 0.18% 106

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Summit Partners Public Asset Management's LENZ Position: Q4 2025 in Review

Summit Partners Public Asset Management sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 323,857 shares — an estimated $15.1M sold.

Summit Partners Public Asset Management first reported a position in LENZ in Q2 2025 and held it in 2 quarters. The position peaked at $15.1M in Q3 2025. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

  • Summit Partners Public Asset Management reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 323,857 LENZ Therapeutics shares in Q4 2025, an estimated $15.1M.
  • Summit Partners Public Asset Management first reported a position in LENZ Therapeutics in Q2 2025 and held it in 2 quarters.
  • Summit Partners Public Asset Management's LENZ Therapeutics position peaked at $15.1M in Q3 2025.
  • 160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.